428 related articles for article (PubMed ID: 33484966)
1. METTL3 restrains papillary thyroid cancer progression via m
He J; Zhou M; Yin J; Wan J; Chu J; Jia J; Sheng J; Wang C; Yin H; He F
Mol Ther; 2021 May; 29(5):1821-1837. PubMed ID: 33484966
[TBL] [Abstract][Full Text] [Related]
2. METTL3 facilitates tumor progression via an m
Li T; Hu PS; Zuo Z; Lin JF; Li X; Wu QN; Chen ZH; Zeng ZL; Wang F; Zheng J; Chen D; Li B; Kang TB; Xie D; Lin D; Ju HQ; Xu RH
Mol Cancer; 2019 Jun; 18(1):112. PubMed ID: 31230592
[TBL] [Abstract][Full Text] [Related]
3. YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer.
Li J; Xie H; Ying Y; Chen H; Yan H; He L; Xu M; Xu X; Liang Z; Liu B; Wang X; Zheng X; Xie L
Mol Cancer; 2020 Oct; 19(1):152. PubMed ID: 33121495
[TBL] [Abstract][Full Text] [Related]
4. FTO suppresses glycolysis and growth of papillary thyroid cancer via decreasing stability of APOE mRNA in an N6-methyladenosine-dependent manner.
Huang J; Sun W; Wang Z; Lv C; Zhang T; Zhang D; Dong W; Shao L; He L; Ji X; Zhang P; Zhang H
J Exp Clin Cancer Res; 2022 Jan; 41(1):42. PubMed ID: 35090515
[TBL] [Abstract][Full Text] [Related]
5. YTHDF2 facilitates UBXN1 mRNA decay by recognizing METTL3-mediated m
Chai RC; Chang YZ; Chang X; Pang B; An SY; Zhang KN; Chang YH; Jiang T; Wang YZ
J Hematol Oncol; 2021 Jul; 14(1):109. PubMed ID: 34246306
[TBL] [Abstract][Full Text] [Related]
6. METTL3-mediated m6A modification of STEAP2 mRNA inhibits papillary thyroid cancer progress by blocking the Hedgehog signaling pathway and epithelial-to-mesenchymal transition.
Zhu Y; Peng X; Zhou Q; Tan L; Zhang C; Lin S; Long M
Cell Death Dis; 2022 Apr; 13(4):358. PubMed ID: 35436987
[TBL] [Abstract][Full Text] [Related]
7. m6A Writer METTL3-Mediated lncRNA LINC01125 Prevents the Malignancy of Papillary Thyroid Cancer.
He T; Xia H; Chen B; Duan Z; Huang C
Crit Rev Immunol; 2023; 43(3):43-53. PubMed ID: 37824376
[TBL] [Abstract][Full Text] [Related]
8. The m
Cheng M; Sheng L; Gao Q; Xiong Q; Zhang H; Wu M; Liang Y; Zhu F; Zhang Y; Zhang X; Yuan Q; Li Y
Oncogene; 2019 May; 38(19):3667-3680. PubMed ID: 30659266
[TBL] [Abstract][Full Text] [Related]
9. METTL3 Promotes Tumorigenesis and Metastasis through BMI1 m
Liu L; Wu Y; Li Q; Liang J; He Q; Zhao L; Chen J; Cheng M; Huang Z; Ren H; Chen J; Peng L; Gao F; Chen D; Wang A
Mol Ther; 2020 Oct; 28(10):2177-2190. PubMed ID: 32621798
[TBL] [Abstract][Full Text] [Related]
10. METTL3-Induced miR-222-3p Upregulation Inhibits STK4 and Promotes the Malignant Behaviors of Thyroid Carcinoma Cells.
Lin S; Zhu Y; Ji C; Yu W; Zhang C; Tan L; Long M; Luo D; Peng X
J Clin Endocrinol Metab; 2022 Jan; 107(2):474-490. PubMed ID: 34562008
[TBL] [Abstract][Full Text] [Related]
11. METTL3/YTHDF2 m
Xie H; Li J; Ying Y; Yan H; Jin K; Ma X; He L; Xu X; Liu B; Wang X; Zheng X; Xie L
J Cell Mol Med; 2020 Apr; 24(7):4092-4104. PubMed ID: 32126149
[TBL] [Abstract][Full Text] [Related]
12. SLC34A2 simultaneously promotes papillary thyroid carcinoma growth and invasion through distinct mechanisms.
He J; Zhou M; Li X; Gu S; Cao Y; Xing T; Chen W; Chu C; Gu F; Zhou J; Jin Y; Ma J; Ma D; Zou Q
Oncogene; 2020 Mar; 39(13):2658-2675. PubMed ID: 32005974
[TBL] [Abstract][Full Text] [Related]
13. m
Hou J; Shan H; Zhang Y; Fan Y; Wu B
Am J Otolaryngol; 2020; 41(4):102547. PubMed ID: 32474328
[TBL] [Abstract][Full Text] [Related]
14. m
Shen C; Xuan B; Yan T; Ma Y; Xu P; Tian X; Zhang X; Cao Y; Ma D; Zhu X; Zhang Y; Fang JY; Chen H; Hong J
Mol Cancer; 2020 Apr; 19(1):72. PubMed ID: 32245489
[TBL] [Abstract][Full Text] [Related]
15. METTL3-dependent N
Chien CS; Li JY; Chien Y; Wang ML; Yarmishyn AA; Tsai PH; Juan CC; Nguyen P; Cheng HM; Huo TI; Chiou SH; Chien S
Proc Natl Acad Sci U S A; 2021 Feb; 118(7):. PubMed ID: 33579825
[TBL] [Abstract][Full Text] [Related]
16. Long noncoding RNA cancer susceptibility candidate 2 suppresses papillary thyroid carcinoma growth by inactivating the AKT/ERK1/2 signaling pathway.
Huang F; Zhang Q; Chen W; Zhang H; Lu G; Chen J; Qiu C
J Cell Biochem; 2019 Jun; 120(6):10380-10390. PubMed ID: 30609134
[TBL] [Abstract][Full Text] [Related]
17. STAT3-induced upregulation of lncRNA ABHD11-AS1 promotes tumour progression in papillary thyroid carcinoma by regulating miR-1301-3p/STAT3 axis and PI3K/AKT signalling pathway.
Wen J; Wang H; Dong T; Gan P; Fang H; Wu S; Li J; Zhang Y; Du R; Zhu Q
Cell Prolif; 2019 Mar; 52(2):e12569. PubMed ID: 30657221
[TBL] [Abstract][Full Text] [Related]
18. METTL3/METTL14 Transactivation and m
Feng Y; Dong H; Sun B; Hu Y; Yang Y; Jia Y; Jia L; Zhong X; Zhao R
Cell Mol Gastroenterol Hepatol; 2021; 12(3):839-856. PubMed ID: 33992834
[TBL] [Abstract][Full Text] [Related]
19. RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2.
Chen M; Wei L; Law CT; Tsang FH; Shen J; Cheng CL; Tsang LH; Ho DW; Chiu DK; Lee JM; Wong CC; Ng IO; Wong CM
Hepatology; 2018 Jun; 67(6):2254-2270. PubMed ID: 29171881
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-222 Promotes Invasion and Metastasis of Papillary Thyroid Cancer Through Targeting Protein Phosphatase 2 Regulatory Subunit B Alpha Expression.
Huang Y; Yu S; Cao S; Yin Y; Hong S; Guan H; Li Y; Xiao H
Thyroid; 2018 Sep; 28(9):1162-1173. PubMed ID: 29882471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
